- Home
- FRME vs KOD Comparison
FRME vs KOD Comparison
Compare FRME & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | KOD |
|---|---|---|
| Founded | 1893 | 2009 |
| Country | United States | United States |
| Employees | 2086 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FRME | KOD |
|---|---|---|
| Price | $39.45 | $44.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $48.33 | $35.43 |
| AVG Volume (30 Days) | 301.8K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.67 | N/A |
| Revenue Next Year | $5.91 | N/A |
| P/E Ratio | $10.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.66 | $3.33 |
| 52 Week High | $43.22 | $47.84 |
Technical Indicators
Market Signals| Indicator | FRME | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 62.71 |
| Support Level | $38.77 | $39.37 |
| Resistance Level | $41.81 | $45.60 |
| Average True Range (ATR) | 0.73 | 3.16 |
| MACD | -0.13 | -0.19 |
| Stochastic Oscillator | 15.17 | 68.04 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.